Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Delcath Systems (DCTH) Other financing activities (2016 - 2020)

Delcath Systems' quarterly Other financing activities came in at $1.9 million in Q4 2020, up 239.6% year-on-year from $548000.0 in Q1 2020, and up 239.6% quarter-over-quarter from $548000.0 in Q4 2019.

Delcath Systems has reported Other financing activities for 4 years, with the latest figure at $1.9 million in Q4 2020.

  • For the quarter ending Q4 2020, Other financing activities rose 239.6% year-over-year to $1.9 million; the trailing twelve-month figure through Dec 2020 stood at $2.4 million (up 339.6% YoY), and the FY2021 full-year result was $886000.0, up 13.44% from the prior year.
  • Other financing activities for Q4 2020 stood at $1.9 million, up from $548000.0 in the prior quarter.
  • The five-year high for Other financing activities was $13.1 million in Q4 2017, with the low at -$5.9 million in Q3 2017.
  • Average Other financing activities over 4 years is $1.9 million, with a median of $396500.0 recorded in 2016.
  • Peak annual rise in Other financing activities reached 2386.12% in 2017, while the deepest fall reached 44.08% in 2017.
  • Tracing DCTH's Other financing activities over 4 years: stood at -$245000.0 in 2016, then surged by 5447.35% to $13.1 million in 2017, then sank by 95.82% to $548000.0 in 2019, then surged by 239.6% to $1.9 million in 2020.
  • The last three Other financing activities figures came in at $1.9 million (Q4 2020), $548000.0 (Q4 2019), and $13.1 million (Q4 2017), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 Delcath Systems 383.27 Mn 293.95 Mn 21.26 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2020 1.86 Mn
Dec 31, 2020 1.86 Mn
Dec 31, 2019 548,000.00
Dec 31, 2019 548,000.00
Dec 31, 2017 13.10 Mn
Dec 31, 2017 13.10 Mn
Sep 30, 2017 -5.94 Mn
Sep 30, 2017 -5.94 Mn
Jun 30, 2017 -137,000.00
Jun 30, 2017 -137,000.00
Mar 31, 2017 6.09 Mn
Mar 31, 2017 6.09 Mn
Jun 30, 2016 -245,000.00
Jun 30, 2016 -245,000.00
Mar 31, 2016 245,000.00
Mar 31, 2016 245,000.00